What's Happening?
AIM ImmunoTech has announced positive results from a Phase 2 clinical trial conducted by the University of Pittsburgh Medical Center (UPMC) for recurrent ovarian cancer. The trial, which evaluated the combination of Ampligen, pembrolizumab, and cisplatin,
reported a 50% Objective Response Rate (ORR) and a 79% Clinical Benefit Rate. The median overall survival was 32.5 months, with some patients experiencing durable responses exceeding 70 months. The study aimed to overcome the immunosuppressive tumor microenvironment in ovarian cancer through immune activation strategies. The trial was financially supported by a grant from Merck.
Why It's Important?
The trial's results suggest that Ampligen, in combination with other therapies, could significantly improve treatment outcomes for patients with recurrent ovarian cancer. This development is crucial as it addresses the challenge of resistance to immunotherapy in ovarian cancer. The promising data could lead to further studies and potential regulatory approvals, expanding treatment options for patients. AIM ImmunoTech's success in this trial enhances its position in the immuno-oncology field and supports its strategy to develop therapies for various cancers and immune disorders.
What's Next?
AIM ImmunoTech plans to collect additional secondary endpoint data, including progression-free survival and overall survival, by January 2027. The company aims to advance Ampligen into later-stage development and explore strategic partnerships to expand its clinical applications. Continued positive results could lead to regulatory submissions and potential market approval, offering new hope for patients with recurrent ovarian cancer.
